Skip to content
value.today

iQure Pharma Inc.

Total raised
$4 M
2 rounds on record
Latest round
$3 M
Sep 2025
First round on record
Oct 2023
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of iQure Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2025$3 MNo. 2$2 to $10 million

iQure Pharma Inc.: Raise no. 2, Sep 2025

Investors in this round

18 investors had bought by the notice of Sep 21, 2026: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Pawel Zolnierczyk · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brianna Roth, Authorized Signatory. Newest notice filed Sep 21, 2026. Read the notice at the SEC.

equitySEC
Oct 2023$2 MNo. 1Under $2 million

iQure Pharma Inc.: Raise no. 1, Oct 2023

Investors in this round

13 investors had bought by the notice of Oct 11, 2023: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Pawel Zolnierczyk · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Pawel Zolnierczyk, President, CEO. Newest notice filed Oct 11, 2023. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • iQure Pharma Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2026).

    SEC Form D · Sep 2026

  • The industry group it chose in its notices: Other.

    SEC Form D · Sep 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of iQure Pharma Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by iQure Pharma Inc.
NameRoleNamed in
Pawel ZolnierczykExecutive officerSep 2026